sFlt-1/PlGF比值联合D-二聚体评估子痫前期妊娠结局的临床价值

The clinical value of sFlt-1/PlGF ratio combined with D-D in assessing the pregnancy outcomes of preeclampsia

摘要

目的 探讨可溶性fms样酪氨酸激酶1(sFlt-1)/胎盘生长因子(PlGF)比值联合D-二聚体(D-D)评估子痫前期(PE)妊娠结局的临床价值。方法 回顾性选取2021年12月至2023年1月收治的102例PE患者作为子痫前期组,另选取同期在我院进行产前检查的正常孕妇60例作为对照组,比较两组28至32周时血清sFlt-1、PlGF、sFlt-1/PlGF比值、D-D水平,采用受试者工作特征(ROC)曲线分析sFlt-1/PlGF比值联合D-D对妊娠结局的预测价值。结果 子痫组血清sFlt-1、sFlt-1/PlGF比值、D-D水平高于对照组,PlGF水平低于对照组(t值分别为10.855、20.310、17.002和15.365,P<0.05);Logistic分析显示,高体质量指数(BMI)、妊娠期糖尿病或肾病、既往子痫前期史、sFlt-1/PlGF比值、D-D均为影响孕妇发生子痫前期的独立危险因素,其OR值及95%CI分别为18.171(6.493~50.849)、4.259(1.096~16.547)、11.367(1.226~105.391)、7.939(2.514~25.068)和1.567(1.330~1.845),P<0.05.不良妊娠结局组血清sFlt-1、sFlt-1/PlGF比值、D-D水平高于非不良妊娠结局组,PlGF水平低于非不良妊娠结局组(t值分别为4.759、5.646、5.331和3.135,P<0.05).ROC曲线显示,sFlt-1/PlGF比值联合D-D预测妊娠结局的曲线下面积(AUC)为0.843,灵敏度和特异度分别为79.41%和75.00%。结论 子痫前期患者血清sFlt-1/PlGF比值、D-D水平升高,二者可用于评估子痫前期妊娠结局.

Abstract

Objective To explore the clinical value of the soluble fms-like tyrosine kinase-1 (sFlt-1)/placental growth factor (PlGF) ratio combined with D-dimer (D-D) in assessing the pregnancy outcomes of preeclampsia (PE). Methods Retrospectively, 102 cases of PE patients admitted from December 2021 to January 2023 were selected as the PE group, while 60 normal pregnant women undergoing prenatal examinations in our hospital during the same period were selected as the control group. The serum sFlt-1, PlGF, sFlt-1/PlGF ratio and D-D at 28 to 32 weeks were compared between the two groups. Receiver operating characteristic (ROC) curve was used to analyze the predictive value of sFlt-1/PlGF ratio combined with D-D for pregnancy outcome. Results Serum levels of sFlt-1, sFlt-1/PlGF ratio and D-D in PE group were higher than those in control group, while PlGF level in the PE group was lower than those in control group (t=10.855, 20.310, 17.002, and 15.365, P<0.05). Logistic analysis showed that high body mass index (BMI), gestational diabetes mellitus or kidney disease, history of PE, sFlt-1/PlGF ratio and D-D were independent risk factors for PE in pregnant women, with OR values and 95%CI of 18.171 (6.493-50.849), 4.259 (1.096-16.547), 11.367 (1.226-105.391), 7.939 (2.514-25.068), and 1.567 (1.330-1.845), respectively, P<0.05. Serum levels of sFlt-1, sFlt-1/PlGF ratio and D-D in adverse pregnancy outcome group were higher than those in good pregnancy outcome group, while PlGF level was lower than those in non-adverse pregnancy outcome group, while PlGF levels in adverse pregnancy outcome group were lower than in the non-adverse pregnancy outcome group (t=4.759, 5.646, 5.331, and 3.135, P<0.05). ROC curves analysis showed that sFlt-1/PlGF ratio combined with D-D had an area under the curve (AUC) of 0.843 for predicting pregnancy outcomes, with sensitivity and specificity of 79.41% and 75.00%, respectively. Conclusion PE patients have elevated serum sFlt-1/PlGF ratio and D-D levels, both of which can be used to assess the pregnancy outcome of PE.

关键词

子痫前期 / 妊娠结局 / 可溶性fms样酪氨酸激酶1 / 胎盘生长因子 / D-二聚体

Key words

preeclampsia / pregnancy outcomes / soluble fms-like tyrosine kinase-1 / placental growth factor / D-dimer

参考文献

[1] Shi P, Zhao L, Yu S, et al. Differences in epidemiology of patients with preeclampsia between China and the US (review)[J]. Exp Ther Med, 2021, 22(3): 1012.

[2] Yang Y, Le Ray I, Zhu J, et al. Preeclampsia prevalence, risk factors, and pregnancy outcomes in Sweden and China[J]. JAMA Netw Open, 2021, 4(5): e218401- e218401.

[3] Wainstock T, Sergienko R, Sheiner E. Who is at risk for preeclampsia? Risk factors for developing initial preeclampsia in a subsequent pregnancy[J]. J Clin Med, 2020, 9(4): 1103.

[4] 于静, 刘丹, 王静远. 子痫前期孕妇血清25-羟维生素D,凝血功能及生化指标等检测对其妊娠结局的预测价值[J]. 临床和实验医学杂志, 2021, 20(7): 753-756.

[5] Chirilă CN, Mărginean C, Chirilă PM, et al. The current role of the sflt-1/plgf ratio and the uterine-umbilical-cerebral doppler ultrasound in predicting and monitoring hypertensive disorders of pregnancy: an update with a review of the literature[J]. Children (Basel), 2023, 10(9): 1430.

[6] Ohkuchi A, Saito S, Yamamoto T, et al. Short-term prediction of preeclampsia using the sFlt-1/PlGF ratio: a subanalysis of pregnant Japanese women from the PROGNOSIS Asia study[J]. Hypertens Res, 2021, 44(7): 813-821.

[7] Rodríguez-Peña Y, Ibáñez-Pinilla M. Elevated levels of D-dimer tested by immunoturbidimetry are associated with the extent of severity of pre-eclampsia[J]. Int J Gynaecol Obstet, 2020, 150(2): 241-247.

[8] 谢幸, 孔北华, 段涛. 妇产科学(第9版)[M]. 北京: 人民卫生出版社, 2018: 84.

[9] Shao H, Gao S, Dai D, et al. The association of antenatal D-dimer and fibrinogen with postpartum hemorrhage and intrauterine growth restriction in preeclampsia[J]. BMC Pregnancy Childbirth, 2021, 21(1): 605.

[10] Dathan-Stumpf A, Rieger A, Verlohren S, et al. sFlt-1/PlGF ratio for prediction of preeclampsia in clinical routine: a pragmatic real-world analysis of healthcare resource utilisation[J]. Plos one, 2022, 17(2): e0263443.

[11] Stepan H, Hund M, Andraczek T. Combining biomarkers to predict pregnancy complications and redefine preeclampsia: the angiogenic-placental syndrome[J]. Hypertension, 2020, 75(4): 918-926.

[12] 罗鸿, 张晓菊, 唐乾坤. 血清ADMA水平、sFlt-1/PlGF比值与子痫前期患者胎盘血流动力学参数的相关性分析[J]. 中国妇幼健康研究, 2022, 33(9): 70-74.

[13] Zuo Q, Zou Y, Huang S, et al. Aspirin reduces sFlt-1-mediated apoptosis of trophoblast cells in preeclampsia[J]. Mol Hum Reprod, 2021, 27(1): gaaa089.

[14] 李辞妹, 杨颖, 毕晶晶, 等. mTOR和PLGF在胎儿宫内生长受限中的作用机制[J]. 基因组学与应用生物学, 2020, 39(1): 326-331.

[15] Jeon H R, Jeong D H, Lee J Y, et al. sFlt-1/PlGF ratio as a predictive and prognostic marker for preeclampsia[J]. J Obstet Gynaecol Res, 2021, 47(7): 2318-2323.

[16] Baboolall U, Zha Y, Gong X, et al. Variations of plasma D-dimer level at various points of normal pregnancy and its trends in complicated pregnancies: a retrospective observational cohort study[J]. Medicine (Baltimore), 2019, 98(23): e15903.

[17] 林少玲, 陈彤华. CTRP9和A-FABP与子痫前期患者脂代谢及炎症因子的关系[J]. 中国妇幼健康研究, 2021, 32(12): 1757-1761.

[18] 黄文英. 血小板及凝血功能参数与子痫前期病情严重程度的关系[J]. 大医生, 2023, 8(20): 130-133.

[19] 段炼, 何国琳. 妊娠期D-二聚体升高带来的临床困惑[J]. 四川大学学报(医学版), 2022, 53(3): 543-548.

[20] Ren Q W, Yang F F, Han T B, et al. Relationship between the pre-pregnancy BMI, gestational weight gain, and risk of preeclampsia and its subtypes[J]. Zhonghua Liu Xing Bing Xue Za Zhi, 2021, 42(11): 2037-2043.

[21] Pankiewicz K, Szczerba E, Fijałkowska A, et al. The impact of coexisting gestational diabetes mellitus on the course of preeclampsia[J]. J Clin Med, 2022, 11(21): 6390.

[22] Usselman C W, Adler T E, Coovadia Y, et al. A recent history of preeclampsia is associated with elevated central pulse wave velocity and muscle sympathetic outflow[J]. Am J Physiol Heart Circ Physiol, 2020, 318(3): H581-H589.

基金资助

秦皇岛市科学技术研究与发展计划项目(201902A048)